{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2851428_A2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"103-622-697-159-709","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11879,"type":"PATENT","title":"Virginia Polytechnic Institute and State University: Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5682,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8482,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
(a) a nucleic acid molecule containing at least one copy of the genomic sequence PTTV2c-VA, or its complementary strand;
(b) a biologically functional plasmid or viral vector containing a nucleic acid molecule containing at least one copy of the genomic sequence PTTV2c-VA, or its complementary strand;
(c) an avirulent, infectious nonpathogenic porcine Torque teno virus, which is derived from and contains a genomic sequence PTTV2c-VA; and
(d) an immunogenic fragment of a polypeptide sequence or a complete protein translated according to a polynucleotide sequence selected from the group consisting of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV2c-VA."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine according to claim 6, wherein the vaccine contains live PTTV virus, preferably wherein the vaccine contains killed PTTV virus."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine according to claim 6, wherein the immunogenic fragment of a polypeptide sequence or a complete protein comprising purified bacterial expressed or baculovirus-expressed recombinant proteins expressed from ORF1, ORF2, ORF1/1 and ORF2/2 of PTTV2c-VA, preferably wherein the immunogenic fragment of a polypeptide sequence or a complete protein comprising purified bacterial expressed or baculovirus-expressed recombinant proteins expressed from ORF1 of PTTV2c-VA."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["An isolated polynucleotide consisting of a polynucleic acid sequence having the nucleotide sequence of PTTV2c-VA set forth in SEQ ID No. 12.."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A vaccine comprising an immunogenic fragment of a polypeptide sequence or a complete protein translated according to a polynucleotide sequence of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV2c-VA."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine of claim 10, wherein the immunogenic fragment or complete protein is a capsid protein of PTTV2c-VA, preferably wherein the polynucleotide sequence is selected from the group consisting of ORF1 of PTTV2c-VA, preferably wherein the polynucleotide sequence sequence is ORF1 of PTTV subtype PTTV2c-VA."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine of claim 10, wherein the polypeptide sequence is selected from the group consisting of sequence set forth in SEQ ID No.16, SEQ ID No.20, SEQ ID No.24, and SEQ ID No.28, preferably
(a) wherein the polypeptide sequence is set forth in SEQ ID No.16, preferably wherein the polypeptide sequence is C-terminal region (310-625) of SEQ ID No.16; or
(b) wherein the polypeptide sequence is set forth in SEQ ID No.20."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine according to claim 6 or claim 10, further containing an adjuvant."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["An immunologically-effective amount of the vaccine according to claim 6 or 10 for use in immunizing a pig against PTTV viral infection."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine for use according to claim 14, wherein the vaccine is the immunogenetic fragment or complete protein."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The vaccine for use according to claim 14, which comprises administering the vaccine parenterally, intranasally, intradermally, or transdermally to the pig, or which comprises administering the vaccine intralymphoidly or intramuscularly to the pig."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["An in vitro method for diagnosing PTTV infection, comprising immobilizing an immunogenetic fragment or a complete protein of a polypeptide sequence translated according to a polynucleotide sequence selected from the group consisting of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV2c-VA; contacting a serum sample from a pig suspected of PTTV infection with the immobilized immunogenetic fragment or complete protein; and detecting captured antibody specific to the immunogenetic fragment."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the polynucleotide sequence is ORF1 of PTTV2c-VA."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the polypeptide sequence is selected from the group consisting of sequence set forth in SEQ ID No.16, SEQ ID No.20, SEQ ID No.24, and SEQ ID No.28, preferably wherein the polypeptide sequence is set forth in SEQ ID No.16."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the immunogenetic fragment is C-terminal region (aa 310-625) of SEQ ID No.16."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the polypeptide sequence is set forth in SEQ ID No.20."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the detecting captured antibody is via Western blot, or wherein the detecting captured antibody is via enzyme-linked immunosorbent assay (ELISA)."],"number":22,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}